miridesap

Miridesap is a first-in-class small molecule that depletes serum amyloid P component (SAP), a protein universally present in amyloid deposits. By binding to circulating SAP and forming complexes that are rapidly cleared by the liver, miridesap reduces SAP levels in the blood and targets systemic amyloidosis. This mechanism disrupts the persistence of amyloid deposits in tissues. Miridesap was originally developed by Pentraxin Therapeutics and later advanced by GlaxoSmithKline for clinical development. It has been investigated primarily for systemic amyloidosis and has also been studied in trials for HIV prevention and Alzheimer's disease[1][3][4][7][8].

Brand names

Miridesap

Other names

1,1'-hexanedioyldi-D-proline(2R,2'R)-1,1'-(1,6-Dioxo-1,6-hexanediyl)di(2-pyrrolidinecarboxylic acid)